CRESEMBA: payments to doctors
Payments that named CRESEMBA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.5M
- Providers
- 5,374
- Transactions
- 15,859
- Average per transaction
- $94
The per-transaction average — $94 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,374 providers the average total is $277, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $1,361,139 | 91.6% |
| Astellas Pharma Global Development | $114,037 | 7.7% |
| Hikma Pharmaceuticals USA | $11,250 | 0.8% |